Articles by Robert Zadotti
Cemiplimab + isatuximab combo shows 51% CR and promising safety in R/R ENKTL, exceeding study endpoint.
Novel PI3Kδ + HDACi combo shows promise for relapsed/refractory CTCL, with favorable outcomes and manageable safety.
The MZL cohort of a phase 2 study saw the most success from the atezolizumab plus obinutuzumab and venetoclax regimen.
Ziftomenib shows strong, lasting responses in R/R NPM1-mutant AML, according to KOMET-001 data shared at EHA 2025.
Brexu-cel shows a significant 5-year OS rate in R/R B-ALL patients, with survival benefits across key subgroups in ZUMA-3.
Elotuzumab added to KRd shows a favorable trend in 3-year PFS for NDMM patients, EHA 2025 study finds.
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
Zanubrutinib and venetoclax show deep and lasting responses in frontline CLL and SLL including those with del 17p or TP53.
Checkpoint inhibitors show promise as second-line salvage therapy in advanced Hodgkin lymphoma, per Philippe Armand, MD, PhD
Experts call for rethinking smoldering myeloma as a distinct disease, with new data supporting early risk-based intervention.
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.